ESSA Pharma
Clinical-stage pharmaceutical company focused on developing the next generation of treatments for prostate cancer
Clinical-stage pharmaceutical company focused on developing the next generation of treatments for prostate cancer
ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 08 Jul 2022 | |
| Post-IPO Equity | Unknown | - | 22 Feb 2021 | |
| Post-IPO Equity | Unknown | - | 12 Jan 2021 | |
| Post-IPO Equity | Unknown | - | 10 Aug 2020 | |
| Post-IPO Equity | Unknown | - | 27 Aug 2019 |
No recent news or press coverage available for ESSA Pharma.
We care about your data, and we'd love to use cookies make your experience better.
